High-dose flu vaccine in rheumatoid arthritis beats standard dose
by Charles C. Chante MD - January 12, 2020 - 12:00am
The administration of high-dose vs. standard-dose influenza vaccine provided substantially better immune responses in seropositive rheumatoid arthritis patients in a randomized, active-controlled trial.
After a fracture, reinforce secondary-prevention message
by Charles C. Chante MD - January 5, 2020 - 12:00am
Ensuring that older adults who have experienced a hip or vertebral fracture understand they likely have osteoporosis, and offering prompt drug treatment for the condition, are among five fundamental recommendations...
No falls, fractures, or bone density benefits from Vitamin D
by Charles C. Chante MD - December 29, 2019 - 12:00am
There is little justification for the use of vitamin D supplementation for the prevention of fractures or falls or for increasing bone density, according to the authors of a meta-analysis that found no benefits from...
Obesity tied to rise of GI, colorectal cancer in younger adults
by Charles C. Chante MD - December 22, 2019 - 12:00am
Researchers have identified a link between obesity and an increased incidence rate of gastrointestinal cancer in younger patients, as well as an increased rate of colorectal, esophageal, and pancreatic cancer resections...
Flu: All that and heart attack too
by Charles C. Chante MD - December 15, 2019 - 12:00am
Myocardial infarction admissions were six times more likely to occur in the week after a positive test for influenza than in the year before or the 51 weeks after the infection, according to analysis of a Canadian...
Long-acting Beta2 agonists didn’t boost BP in COPD
by Charles C. Chante MD - December 8, 2019 - 12:00am
Neither heart rate nor blood pressure worsened under long-term use of long-acting beta2 agonists olodaterol or formoterol in patients with chronic obstructive pulmonary disease, according to a post hoc pooled analysis...
‘Undetectable’ HIV means ‘untransmissible’ confirmed in larger sex study
by Charles C. Chante MD - December 1, 2019 - 12:00am
One maxim of current HIV management is U=U; Undetectable equals Untransmissible, and it received new backing for the specific question of whether HIV treated to an undetectable level can transmit from a man who engages...
Next-gen sputum PCR panel boosts CAP diagnostics
by Charles C. Chante MD - November 24, 2019 - 12:00am
A next-generation lower respiratory tract sputum polymerase chain reaction film array panel identified etiologic pathogens in 100 percent of a group of patients hospitalized for community-acquired pneumonia.
Rising US PrEP use linked with dropping HIV infections
by Charles C. Chante MD - November 17, 2019 - 12:00am
Pre exposure prophylaxis against HIV infection by US residents appears to be paying off: The number of new US HIV infections among those at least 13 years old dropped during 2012-2016, and this decline showed a statistically...
Statin use is uniformly in adults with dyslipidemia disorders
by Charles C. Chante MD - November 10, 2019 - 12:00am
Only half of adults with familial hypercholesterolemia are currently in statin therapy, with even fewer receiving a high-intensity statin, according to an analysis of data from the National Health and Nutrition Examination...
Breast arterialcalcification low bonemass predicted CAD in women
by Charles C. Chante MD - November 3, 2019 - 12:00am
Breast arterial calcification and low bone mass were strongly linked to risk of coronary artery disease in asymptomatic women, according to cross-sectional registry study.
USPSTF: Insufficient evidence for ankle-branchial index screening
by Charles C. Chante MD - October 27, 2019 - 12:00am
There’s not enough evidence to recommend – or not recommend – routine ankle-brachial index screening for peripheral artery disease in asymptomatic adults without known cardiovascular or chronic...
EULAR recommendations on steroids: ‘As necessary but as little as possible’
by Charles C. Chante MD - October 20, 2019 - 12:00am
Glucocorticosteroids remain an important therapeutic option for many patients with rheumatic and nonrheumatic disease, but careful assessment of their relative benefits and risks needs to be considered when prescribing,...
How to prioritize CV risk reduction in type 2 diabetes
by Charles C. Chante MD - October 13, 2019 - 12:00am
The pooled analysis showed that initiation of SGLT2 inhibitors was associated with a significantly lower risk of heart failure events, compared with other glucose-lowering drugs (risk ration, 0.61; P less than .001.)....
How to prioritize CV risk reduction in type 2 diabetes
by Charles C. Chante MD - October 6, 2019 - 12:00am
In the opinion of a doctor, the paradigm of treating patients with type 2 diabetes should shift from a narrow focus on hemoglobin A control to a broader strategy of reducing cardiovascular risk.
Failure to prevent most heart failure could be avoided
by Charles C. Chante MD - September 29, 2019 - 12:00am
Until the randomized EMPA-REG-OUTCOME trial of the sodium-glucose transporter 2 (SGLT-2) inhibitors empagliflozin (Jardiance), no glucose-lowering drug available for treatment of type 2 diabetes had shown any benefit...
Failure to prevent most heart failure could be avoided
by Charles C. Chante MD - September 22, 2019 - 12:00am
More than 960,000 new cases of heart failure will occur in the United States this year – and most of them could have been prevented, asserted at Annual Cardiovascular Conference.
Long-term effects of using ketamine for depression are uncertain
by Charles C. Chante MD - September 15, 2019 - 12:00am
Low doses of ketamine, an N- methyl- D- aspirate glutamate receptor antagonist, can produce benefits that are unprecedented in the history of treating major depression.
Ledipasvir/Sofosbuvir looks good in HBV-coinfected patients
by Charles C. Chante MD - September 8, 2019 - 12:00am
For patients with chronic hepatitis C and hepatitis B virus co-infection, 12 weeks of ledipasvir/sofosbuvir therapy achieved a 100 percent sustained viral response rate without causing liver failure or death in a...
Case for rivaroxaban and aspirin for pad gets stronger
by Charles C. Chante MD - September 1, 2019 - 12:00am
Combination treatment with aspirin and low dosage of the anticoagulant rivaroxaban has a broader benefit for reducing adverse events in patients with peripheral artery disease than initially reported from the COMPASS...
1 | 2 | 3 | 4 | 5 | ... | 38 | 39 | 40 | 41 | 42
Are you sure you want to log out?
Login is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

or sign in with